Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 18/20 | 0.69 |
| ▸ | ABL1 | P00519 | 17/20 | 0.69 |
| ▸ | MTOR | P42345 | 17/20 | 0.69 |
| ▸ | PIK3CD | O00329 | 17/20 | 0.69 |
| ▸ | PIK3CA | P42336 | 17/20 | 0.69 |
| ▸ | PIK3CB | P42338 | 17/20 | 0.69 |
| ▸ | PIK3CG | P48736 | 17/20 | 0.69 |
| ▸ | PRKDC | P78527 | 16/20 | 0.69 |
| ▸ | EGFR | P00533 | 15/20 | 0.69 |
| ▸ | HCK | P08631 | 15/20 | 0.69 |
| ▸ | KDR | P35968 | 15/20 | 0.69 |
| ▸ | EPHB4 | P54760 | 15/20 | 0.69 |
| ▸ | PI4KB | Q9UBF8 | 7/20 | 0.66 |
| ▸ | BACE1 | P56817 | 2/20 | 0.64 |
| ▸ | RICTOR | Q6R327 | 1/20 | 0.61 |
| ▸ | RPTOR | Q8N122 | 1/20 | 0.61 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.61 |
| ▸ | MAPKAP1 | Q9BPZ7 | 1/20 | 0.61 |
| ▸ | MLST8 | Q9BVC4 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12607034 | 0.83 | SRC (0.67) | SRCABL1MTORPIK3CDPIK3CA | |
| SCHEMBL16601548 | 0.83 | SRC (0.67) | SRCABL1MTORPIK3CDPIK3CA | |
| SCHEMBL1785138 | 0.80 | SRC (0.62) | SRCABL1MTORPIK3CDPIK3CA | |
| SCHEMBL3610515 | 0.80 | SRC (1.00) | SRCABL1MTORPIK3CDPIK3CA | |
| SCHEMBL24096629 | 0.79 | SRC (0.84) | SRCABL1MTORPIK3CDPIK3CA | |
| SCHEMBL30320624 | 0.79 | SRC (0.84) | SRCABL1MTORPIK3CDPIK3CA | |
| SCHEMBL19645242 | 0.79 | SRC (0.67) | SRCABL1MTORPIK3CDPIK3CA | |
| SCHEMBL14574574 | 0.79 | SRC (0.80) | SRCABL1MTORPIK3CDPIK3CA | |
| SCHEMBL3615741 | 0.79 | SRC (1.00) | SRCABL1MTORPIK3CDPIK3CA | |
| SCHEMBL1320779 | 0.78 | SRC (0.80) | SRCABL1MTORPIK3CDPIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3009436-B1 | KINASE INHIBITORS AND METHODS OF USE | INTELLIKINE LLC (US) | 2019-06-05 | — | — | EP | disclosed |
| US-9828378-B2 | Kinase inhibitors and methods of use | INTELLIKINE LLC (US) | 2017-11-28 | — | — | US | disclosed |
| US-9828378-B2 | Kinase inhibitors and methods of use | INTELLIKINE LLC (US) | 2017-11-28 | — | — | US | disclosed |
| US-9637492-B2 | Benzothiazole kinase inhibitors and methods of use | INTELLIKINE LLC (US) | 2017-05-02 | — | — | US | disclosed |
| US-9637492-B2 | Benzothiazole kinase inhibitors and methods of use | INTELLIKINE LLC (US) | 2017-05-02 | — | — | US | disclosed |
| EP-3009436-A1 | KINASE INHIBITORS AND METHODS OF USE | Intellikine, LLC (US) | 2016-04-20 | — | — | EP | disclosed |
| US-20160024099-A1 | KINASE INHIBITORS AND METHODS OF USE | INTELLIKINE LLC | 2016-01-28 | — | — | US | disclosed |
| US-20160024099-A1 | KINASE INHIBITORS AND METHODS OF USE | INTELLIKINE LLC | 2016-01-28 | — | — | US | disclosed |
| EP-2313414-B1 | KINASE INHIBITORS AND METHODS OF USE | INTELLIKINE LLC (US) | 2015-11-04 | — | — | EP | disclosed |
| US-20150225407-A1 | Benzothiazole Kinase Inhibitors and Methods of Use | INTELLIKINE LLC | 2015-08-13 | — | — | US | disclosed |
| US-9096611-B2 | Kinase inhibitors and methods of use | INTELLIKINE LLC (US) | 2015-08-04 | — | — | US | disclosed |
| US-9096611-B2 | Kinase inhibitors and methods of use | INTELLIKINE LLC (US) | 2015-08-04 | — | — | US | disclosed |
| US-8993580-B2 | Benzothiazole kinase inhibitors and methods of use | INTELLIKINE LLC (US) | 2015-03-31 | — | — | US | disclosed |
| US-8993580-B2 | Benzothiazole kinase inhibitors and methods of use | INTELLIKINE LLC (US) | 2015-03-31 | — | — | US | disclosed |
| US-20110172228-A1 | KINASE INHIBITORS AND METHODS OF USE | INTELLIKINE LLC | 2011-07-14 | — | — | US | disclosed |
| US-20110172228-A1 | KINASE INHIBITORS AND METHODS OF USE | INTELLIKINE LLC | 2011-07-14 | — | — | US | disclosed |
| US-20110124641-A1 | BENZOTHIAZOLE KINASE INHIBITORS AND METHODS OF USE | INTELLIKINE LLC | 2011-05-26 | — | — | US | disclosed |
| US-20110124641-A1 | BENZOTHIAZOLE KINASE INHIBITORS AND METHODS OF USE | INTELLIKINE LLC | 2011-05-26 | — | — | US | disclosed |
| WO-2010006086-A2 | KINASE INHIBITORS AND METHODS OF USE | INTELLIKINE, INC. (US) | 2010-01-14 | — | — | WO | disclosed |
| WO-2009114874-A2 | BENZOTHIAZOLE KINASE INHIBITORS AND METHODS OF USE | INTELLIKINE, INC. (US) | 2009-09-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172228-A1 | KINASE INHIBITORS AND METHODS OF USE | PIK3CA, MTOR, PDPK1 | SRC 54/4885ABL1 73/4885MTOR 2/4885 |
| US-20110124641-A1 | BENZOTHIAZOLE KINASE INHIBITORS AND METHODS OF USE | MTOR, PDPK1, PIKFYVE | SRC 164/4885ABL1 93/4885MTOR 1/4885 |
| US-20150225407-A1 | Benzothiazole Kinase Inhibitors and Methods of Use | MTOR, PDPK1, PIKFYVE | SRC 164/4885ABL1 93/4885MTOR 1/4885 |
| US-20160024099-A1 | KINASE INHIBITORS AND METHODS OF USE | PIK3CA, MTOR, PDPK1 | SRC 54/4885ABL1 73/4885MTOR 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.